Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BERRY GLOBAL GROUP, INC.BERY · Entity 80192 | Director | November 25, 2023 | November 28, 2023 |
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Chief Financial Officer | May 11, 2026 | May 12, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BERRY GLOBAL GROUP, INC.
Report date November 25, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,728 |
Reported balance
After 2023-11-25 transaction · row 1
1 source rowRow 1 · 2023-11-25 · Exercise / conversion · Acquired 1,970 · Balance 4,728 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,393 |
Reported balance
After 2023-11-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-25 · Exercise / conversion · Disposed 1,970 · Balance 1,393 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023.
Edwards Lifesciences Corp
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,740 |
Ending reported balance
After 2026-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-11 · Exercise / conversion · Acquired 19,830 · Balance 57,744 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Row 2 · 2026-05-11 · Tax withholding · Disposed 11,004 · Balance 46,740 |
| Performance RightsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-11 · Exercise / conversion · Disposed 19,830 · Balance 0 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2: These Performance Rights expire on May 10, 2030. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 266,318 |
Reported balance
Holding disclosure · report date 2026-05-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 266,318 |
Filing footnotes · ownership attribution and instrument terms
F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
F2: These Performance Rights expire on May 10, 2030.
ILLUMINA, INC.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,143 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 113 · Balance 11,143 F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2020 Filed May 13, 2020 20:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 750 | $217.84 | $163,380.00 |
DisclosureSEC source: 0001225208-20-007578 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,869 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007578 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007340 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,575 Underlying: Common Stock · 2,575 shares Expires 2027-05-06 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 18,700 | $0.00 Strike: $218.04 | $0.00 |
DisclosureSEC source: 0001225208-20-007340 · doc4.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2027-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007340 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,013 F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| January 07, 2020 Filed Jan 7, 2020 20:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,500 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-20-000615 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,600 Underlying: Common Stock · 7,500 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| January 07, 2020 Filed Jan 7, 2020 20:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,500 | $234.25 | $1,756,875.00 |
DisclosureSEC source: 0001225208-20-000615 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,938 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| January 07, 2020 Filed Jan 7, 2020 20:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,500 | $41.94 | $314,550.00 |
DisclosureSEC source: 0001225208-20-000615 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 00:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,500 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-015604 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,100 Underlying: Common Stock · 7,500 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 00:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,500 | $233.88 | $1,754,100.00 |
DisclosureSEC source: 0001225208-19-015604 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,938 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 00:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,500 | $41.94 | $314,550.00 |
DisclosureSEC source: 0001225208-19-015604 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 22:24 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $45.60 | $0.00 |
DisclosureSEC source: 0001567619-19-022306 · doc1.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 11,500 shares Expires 2029-11-24 F1 · derivative.exercise_date: Granted under the 2015 Long-Term Incentive Plan. Option fully vested. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 22:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,500 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-014404 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,600 Underlying: Common Stock · 7,500 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 22:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,500 | $234.28 | $1,757,100.00 |
DisclosureSEC source: 0001225208-19-014404 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,938 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 22:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,500 | $41.94 | $314,550.00 |
DisclosureSEC source: 0001225208-19-014404 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| October 29, 2019 Filed Oct 30, 2019 16:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,500 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-013933 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,100 Underlying: Common Stock · 7,500 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| October 29, 2019 Filed Oct 30, 2019 16:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,500 | $235.30 | $1,764,750.00 |
DisclosureSEC source: 0001225208-19-013933 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,938 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| October 29, 2019 Filed Oct 30, 2019 16:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,500 | $41.94 | $314,550.00 |
DisclosureSEC source: 0001225208-19-013933 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 16:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 3,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-013933 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 71,588 Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 16:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 3,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-013933 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,938 Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 00:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,500 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-012275 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 7,500 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 00:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,500 | $225.74 | $1,693,050.00 |
DisclosureSEC source: 0001225208-19-012275 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 00:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,500 | $41.94 | $314,550.00 |
DisclosureSEC source: 0001225208-19-012275 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 01:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,500 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-011904 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,100 Underlying: Common Stock · 7,500 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 01:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,500 | $213.44 | $1,600,800.00 |
DisclosureSEC source: 0001225208-19-011904 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 01:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,500 | $41.94 | $314,550.00 |
DisclosureSEC source: 0001225208-19-011904 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 26, 2019. Read SEC document |
| May 14, 2019 Filed May 14, 2019 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,104 | $178.17 | $196,699.68 |
DisclosureSEC source: 0001225208-19-007998 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,564 Read SEC document |
| May 12, 2019 Filed May 14, 2019 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007998 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,784 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.exercise_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.expiration_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.underlying_shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 14, 2019 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,236 | $181.10 | $223,839.60 |
DisclosureSEC source: 0001225208-19-007998 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,668 F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 14, 2019 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 506 | $181.10 | $91,636.60 |
DisclosureSEC source: 0001225208-19-007998 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,904 Read SEC document |
| May 12, 2019 Filed May 14, 2019 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007998 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 08, 2019 Filed May 10, 2019 18:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 2,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000027 · primary_doc.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,825 Underlying: Common Stock · 2,825 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 18:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 19,900 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000027 · primary_doc.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,900 Underlying: Common Stock · 19,900 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 18:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000027 · primary_doc.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,626 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| February 21, 2019 Filed Feb 27, 2019 01:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 575 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003784 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,376 F1 · shares: These restricted stock units were granted on February 21, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 16:59 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantDirector Stock Option (Right To Buy) · Derivative | 8,000 | $0.00 Strike: $49.90 | $0.00 |
DisclosureSEC source: 0001567619-19-002457 · doc1.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 8,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: Granted under the 2015 Long-Term Incentive Plan. Option fully vested. Read SEC document |
| October 03, 2018 Filed Feb 13, 2019 00:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 5,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002327 · doc5.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 67,962 Read SEC document |
| October 03, 2018 Filed Feb 13, 2019 00:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 5,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002327 · doc5.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,801 Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 22:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,036 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001225208-18-013252 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,036 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 22:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 20,936 | $139.81 | $2,927,097.75 |
DisclosureSEC source: 0001225208-18-013252 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,983 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $139.32 to $140.31. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 22:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,300 | $140.76 | $323,748.00 |
DisclosureSEC source: 0001225208-18-013252 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $140.32 to $141.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 22:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,800 | $141.81 | $255,261.96 |
DisclosureSEC source: 0001225208-18-013252 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,219 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $141.43 to $142.09. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 22:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,036 | $34.05 | $852,475.80 |
DisclosureSEC source: 0001225208-18-013252 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001225208-18-012712 · doc4.xml · derivative · entry 7 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,036 Underlying: Common Stock · 25,000 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,700 | $137.14 | $1,193,160.63 |
DisclosureSEC source: 0001225208-18-012712 · doc4.xml · nonDerivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,983 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F5 · price: This transaction was executed in multiple trades at prices ranging from $136.58 to $137.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,522 | $135.10 | $1,016,189.10 |
DisclosureSEC source: 0001225208-18-012712 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $134.58 to $135.54. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,169 | $137.86 | $712,594.20 |
DisclosureSEC source: 0001225208-18-012712 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,205 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $137.58 to $138.14. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,609 | $136.10 | $491,168.30 |
DisclosureSEC source: 0001225208-18-012712 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,374 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $135.58 to $136.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,000 | $34.05 | $851,250.00 |
DisclosureSEC source: 0001225208-18-012712 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 22:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 282 | $146.99 | $41,451.18 |
DisclosureSEC source: 0001225208-18-011636 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,983 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.